Table 4 The data set involved in this article, Ratio represents the unbalanced ratio of the data set
ID | Dataset | Pos/Neg | Samples | Features | Ratio | Summary |
|---|---|---|---|---|---|---|
1 | Adenoma | 18/18 | 36 | 7457 | 1.00 | Colon adenocarcinoma (18) and normal (18) |
2 | ALL_AML | 47/25 | 72 | 7129 | 1.88 | ALL (47) and AML(25) |
3 | ALL1 | 95/33 | 128 | 12,625 | 2.88 | B-cell (95) and T-cell (33) |
4 | ALL2 | 65/35 | 100 | 12,625 | 1.86 | Patients that did (65) and did not (35) relapse |
5 | ALL3 | 24/101 | 125 | 12,625 | 0.24 | With (24) and without (101) multidrug resistance |
6 | ALL4 | 26/67 | 93 | 12,625 | 0.39 | With (26) and without (67) the t(9;22) chromosome translocation |
7 | CNS | 39/21 | 60 | 7129 | 1.86 | Medulloblastoma survivors (39) and treatment failures (21) |
8 | Colon | 40/22 | 62 | 2000 | 1.82 | Tumour (40) and normal (22) |
9 | DLBCL | 58/19 | 77 | 7129 | 3.05 | DLBCL patients (58) and follicular lymphoma (19) |
10 | Gastric | 29/36 | 65 | 22,645 | 0.81 | Tumors (29) and non-malignants (36) |
11 | Leukaemia | 47/25 | 72 | 7129 | 1.88 | ALL (47) and AML (25) |
12 | Lymphoma | 22/23 | 45 | 4026 | 0.96 | Germinalcentre (22) and activated B-like DLBCL (23) |
13 | Myeloma | 137/36 | 173 | 12,625 | 3.81 | Presence (137) and absence (36) of focallesions of bone |
14 | Prostate | 52/50 | 102 | 12,625 | 1.04 | Prostate (52) and non-prostate (50) |
15 | Stroke | 20/20 | 40 | 54,675 | 1.00 | Ischemic stroke (20) and control (20) |
16 | CLP-prot | 30/30 | 60 | 1042 | 1.00 | Mothers with CLP-affected fetuses(30) and with normal controls (30) |